Curis Inc (NASDAQ:CRIS) Shorts Decreased By 12.89%

April 16, 2018 - By Lena Young

Curis, Inc. (NASDAQ:CRIS) Corporate Logo

During Q4 2017 the big money sentiment increased to 1.59. That’s change of 0.11, from 2017Q3’s 1.48. 6 investors sold all, 21 reduced holdings as Curis, Inc. ratio is positive. 29 grew positions while 14 funds amassed positions. Funds hold 75.55 million shares thus 1.01% less from 2017Q3’s 76.32 million shares.
Focused Wealth holds 0.04% or 184,490 shs in its capital. California State Teachers Retirement Systems, California-based fund reported 208,456 shs. Rhumbline Advisers invested 0% of its capital in Curis, Inc. (NASDAQ:CRIS). Panagora Asset Management Inc holds 0% of its capital in Curis, Inc. (NASDAQ:CRIS) for 806,793 shs. National Bank Of Mellon Corp accumulated 361,445 shs. Millennium Mgmt Ltd Liability Company invested 0% in Curis, Inc. (NASDAQ:CRIS). Bankshares Of America Corp De holds 0% or 119,879 shs. Sg Americas Llc owns 269,128 shs for 0% of their capital. California Public Employees Retirement Systems stated it has 210,300 shs. Bridgeway Capital Mgmt has invested 0% in Curis, Inc. (NASDAQ:CRIS). Susquehanna International Group Llp holds 56,946 shs. Bnp Paribas Arbitrage Sa has invested 0% in Curis, Inc. (NASDAQ:CRIS). Blackrock Incorporated reported 9.72 million shs. Mackenzie Fincl stated it has 0% of its capital in Curis, Inc. (NASDAQ:CRIS). Moreover, Prelude Capital Mngmt Ltd Liability Corporation has 0% invested in Curis, Inc. (NASDAQ:CRIS) for 2,306 shs.

It was recorded a decrease on Curis Inc (NASDAQ:CRIS)’s shares shorted with 12.89%. In April was issued CRIS’s total 2.50M shares shorted by FINRA. That’s 12.89% down from 2.87 million shares. With Average volume 1.74M, CRIS’s previous position will take 1 days to recover. Curis Inc float short is 1.85%.

The stock increased 2.24% or $0.0136 during the last trading session, reaching $0.6197.Currently Curis, Inc. is downtrending after 76.80% change in last April 16, 2017. CRIS has 681,217 shares volume. CRIS underperformed the S&P 500 by 88.35%.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.The company has $102.64 million market cap. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.Last it reported negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.

Curis, Inc. (NASDAQ:CRIS) Ratings Coverage

Total analysts of 2 have positions in Curis Inc (NASDAQ:CRIS) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since October 23, 2017 according to StockzIntelligence Inc Curis Inc has 2 analyst reports. On Monday, October 23 the company was initiated by Guggenheim.

Curis, Inc. (NASDAQ:CRIS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.